KONEXBiotech & Pharma390110

anymedi

₩578▼ 15.00%2026-10-02 close

Market Cap

₩5.6B

Turnover

₩1,685,154

Volume

2,260 shares

Shares out.

9.7M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Improving Fundamentals, Diverging Stock Price

Fiscal 2024 delivered 21% revenue growth and a 42% narrowing of operating losses, yet persistent deficits and extreme KONEX illiquidity mean that the pace of commercialization for AI surgical robotics and global expansion remains the pivotal variable for any re-rating.

1
FY2024 standalone: revenue +21% YoY, operating loss -42%, net loss -29.1% — improvement confirmed despite Korea's 2024 medical-staffing shortage
2
'Innofit' rhinoplasty implant remains the top revenue driver through ASP hikes and wider clinic distribution; initial overseas entry into Vietnam underway
3
Formal AI surgical robot market entry announced February 2025, with a marker-less perioperative joint-replacement robot under development
4
Joint clinical program with U.S. Anschutz Medical Campus and Asan Medical Center underway (2023–2026), backed by ~KRW 2.85 billion in government funding
5
Stock at KRW 300 with daily turnover of ~KRW 111,570 (as of 2026-06-07) — extreme KONEX illiquidity virtually eliminates meaningful price discovery

Business structure

Anymedi Solution was spun off in December 2016 from the Medical Imaging and Intelligent Reality Laboratory (MI2RL) at Asan Medical Center's Radiology and Convergence Medicine departments by clinical translational research specialists.

Headquartered in Hanam, Gyeonggi-do, and led by CEO Kim Guk-bae, the company had approximately 32 employees as of March 2025—a lean technology venture.

Its core business spans three product lines built on AI-based medical imaging analysis and 3D printing: ① surgical simulators, ② patient-customized surgical guides, and ③ customized implants and prosthetics.

As of 2022, implants (led by 'Innofit') accounted for ~43% of revenue, surgical guides ~25%, and simulators ~19%; the implant share is estimated to have expanded further following ASP hikes and wider distribution.

In surgical guides, co-sales agreements with global orthopedics firms Exactech and LIMA cover shoulder-joint implant/guide packages, while a similar packaging arrangement with Stryker and Johnson & Johnson is being developed for orbital fracture implants.

With over 3,000 clinical studies validating product safety and efficacy, and the most extensive new medical technology certifications and insurance listings among domestic digital health companies, the company has built meaningful regulatory moats.

The competitive landscape for patient-customized medical devices remains nascent with no directly comparable listed peers, though AI medical imaging startups like Medical IP pursuing KOSDAQ tech-exception listings are intensifying the emerging competitive dynamic.

In early 2025, the company formally added AI surgical robotics as a new pillar, combining its existing orthopedic surgical planning software platform with a deep-learning imaging module to develop a marker-less robotic system—a natural extension of its established capabilities.

Recent trends

On a 2024 full-year standalone basis, revenue rose 21% YoY, operating loss contracted 42%, and net loss declined 29.1%, confirming a visible improvement trajectory. Innofit ASP hikes, wider clinic distribution, and higher surgical guide volumes were the primary growth drivers.

Notably, these gains were achieved despite the severe domestic medical-staffing shortage that began in March 2024 and sharply curtailed major-hospital procedure volumes—a meaningful signal of underlying demand resilience.

In February 2025, the company officially launched 'Quick4You,' a same-day rhinoplasty service for international medical tourists, targeting the Southeast Asian and Japanese visitor pool; the company cited increased clinical volume and accelerated AI-driven design cycles as enabling factors.

The same month saw the formal announcement of AI surgical robot market entry, signaling management's intent to expand beyond adjunct surgical products. The Innofit implant also made its initial overseas foray in Vietnam, with Thailand and other countries slated as subsequent targets.

On the stock price front, the share declined from approximately KRW 1,693 in mid-2025 (per Hankyung chart data) to KRW 300 as of June 7, 2026—a fall of over 80% from the KRW 2,300 52-week high.

Daily turnover of approximately KRW 111,570 at the reference date indicates near-complete absence of normal market transactions, reflecting persistent seller pressure and a dearth of buying interest.

The lean organizational structure of approximately 32 employees also represents an inherent constraint on execution capacity for product diversification and business scaling.

Outlook

In the near term, the key commercial catalysts are the ramp-up of 'Quick4You' international rhinoplasty services and market localization in Vietnam and broader Southeast Asia.

The global medical aesthetics market is forecast to grow from USD 83.6 billion in 2023 to USD 199.8 billion by 2031, and Korea's world-leading per-capita cosmetic procedure rate underpins durable domestic demand.

The surgical robot market timing appears favorable: global sales are projected to grow at a 6.6% CAGR from USD 9.6 billion (2021) to USD 17 billion (2030), while Korea's domestic market is expanding at an estimated 21.5% annually.

However, the path from AI surgical robot development to commercial revenue—spanning clinical trials, regulatory clearance, insurance reimbursement listing, and hospital adoption—typically requires multiple years, capping near-term earnings contribution.

The conclusion of the joint clinical program with the University of Colorado Anschutz Medical Campus in 2026 would materially strengthen the technical proof base for a subsequent U.S. market push.

Achieving operational breakeven and realizing a KOSDAQ transfer listing remain the pivotal re-rating catalysts that must precede any escape from the current extreme-illiquidity, depressed-price dynamic.

Bull factors

Concurrent Revenue Growth and Loss Improvement

Fiscal 2024 delivered 21% revenue growth, a 42% reduction in operating loss, and a 29.1% decline in net loss, making the structural improvement trajectory visible. Sustaining 20%+ top-line growth despite Korea's severe medical-staffing shortage headwind demonstrates meaningful demand resilience in core product lines.

Simultaneous ASP hikes and distribution network expansion for Innofit are creating a virtuous cycle of volume growth and margin improvement that could accelerate profitability.

If this trend is maintained, the breakeven timeline could move forward meaningfully, representing a key monitoring variable for medium-term investors.

AI Surgical Robotics Dramatically Expands TAM

The February 2025 AI surgical robot market entry declaration dramatically expands the addressable market well beyond existing surgical adjunct products.

Development of a marker-less robotic system built on the existing orthopedic surgical planning software platform—enhanced by a deep-learning imaging module—represents a natural extension of established capabilities rather than a leap into an unfamiliar domain.

The global surgical robotics market is projected to grow at 6.6% CAGR through 2030, with Korea's domestic market expanding at 21.5% annually, validating the entry timing.

The 3,000+ accumulated clinical data records and regulatory infrastructure already in place provide a meaningful head-start versus pure-play new entrants in this space.

Building Global Clinical and IP Moats

A government-funded joint clinical program with Asan Medical Center and the University of Colorado Anschutz Medical Campus (KRW 2.85 billion, 2023–2026) is building the clinical evidence base essential for eventual U.S. market entry.

Multiple U.S. patents have been granted—including the rhinoplasty prosthetic manufacturing method and kidney cancer surgical guide—and two consecutive years on MedTech Outlook's 'Top 10 Medical Solutions Companies' list reflect growing international recognition.

Innofit's commercial expansion from Vietnam into the broader Southeast Asian medical tourism market, accelerated by the 'Quick4You' same-day surgery service, is opening new global demand channels.

Domestically, the record-setting new medical technology certifications and insurance listing history constitute regulatory moats that are genuinely difficult for competitors to replicate quickly.

Bear factors

Persistent Losses with No Clear Breakeven Timeline

The company has generated operating losses since inception, and despite a 42% reduction in the deficit in 2024, breakeven remains out of reach.

With operating losses reported at approximately KRW 6.5 billion in 2022 against a still-modest revenue base, R&D and SG&A expenses structurally outpace the pace of monetization.

A prior failed attempt at a KOSDAQ listing—reportedly due to inadequate financial performance—highlights the slow pace of financial improvement.

With no clearly visible breakeven timeline, the risk of cash depletion and the need for additional funding remain ever-present; incremental capital expenditure for AI surgical robot development further compounds the balance sheet burden.

Extreme KONEX Illiquidity and Severe Price Decline

As of June 7, 2026, the stock trades at KRW 300 with daily turnover of approximately KRW 111,570—rendering meaningful price discovery virtually impossible.

Relative to approximately KRW 1,693 in mid-2025 (per Hankyung chart data), the current price represents a decline of over 80%; the drawdown from the KRW 2,300 52-week high is even more severe.

The KONEX market's structural barriers to institutional and foreign investor participation keep the investable universe extremely narrow, making it difficult to find counterparties when exiting positions.

Until a KOSDAQ transfer listing is achieved, structural improvement in liquidity remains unlikely, keeping price volatility risk persistently elevated.

Structurally Slow Hospital Adoption Cycle

Hospital markets are inherently slow to adopt new technologies from venture companies; the company itself acknowledges in its disclosures that commercialization in hospital settings takes considerable time.

The requirement for per-hospital product code registration creates a structural drag on sales efficiency at scale.

For the AI surgical robot specifically, the sequential hurdles of clinical trials, regulatory approval, insurance reimbursement listing, and actual hospital adoption typically span multiple years, making near-term earnings contribution from the new business unrealistic.

This structural dynamic extends the time-lag between R&D investment and revenue conversion, prolonging the period of financial pressure.

Risk factors

Financial Risk

Persistent operating losses continue to widen the accumulated deficit, making the feasibility, terms, and timing of future fundraising a critical variable for business continuity.

With cumulative funding exceeding approximately KRW 30 billion as of 2023, future capital raises will require increasingly concrete performance proof from investors. Incremental capex for AI surgical robot development layered on top of an existing deficit structure risks deepening the financial burden materially.

A prolonged delay in a KOSDAQ transfer listing would channel fundraising into KONEX-stage private placements, raising the cost of capital and amplifying dilution risk.

Regulatory & Clinical Risk

AI-based surgical solutions and surgical robots are subject to rigorous medical device regulations—from Korea's MFDS to the U.S. FDA—and any approval delays or rejections could materially disrupt the business plan.

Domestic National Health Insurance listing remains a pivotal determinant of commercialization speed, and the new medical technology assessment process entails substantial inherent uncertainty.

The U.S. joint clinical program with the Anschutz Medical Campus (2023–2026) is a prerequisite for FDA clearance, but the subsequent 510(k) or PMA review may demand additional clinical evidence, potentially delaying U.S. market entry beyond current expectations.

Divergent regulatory frameworks across target export markets add compounding cost and time risks to the international expansion strategy.

Macro & Sector Risk

As demonstrated by Korea's 2024 medical-staffing shortage, sudden healthcare policy disruptions can directly curtail procedure volumes at the hospital customer base.

Elective cosmetic procedures are highly cyclical consumption goods; a macroeconomic downturn could rapidly compress demand, and given the current dependence on Innofit revenues, cyclicality risk should not be underestimated.

The Innofit overseas strategy's reliance on K-beauty medical tourism from Southeast Asia and Japan exposes the company to external variables including KRW appreciation, visa policy tightening, and geopolitical disruptions.

There is also a structural risk that major global implant manufacturers such as Stryker and Johnson & Johnson may internalize customized solutions or launch competitive products, potentially undermining the existing collaborative sales arrangements.

Overall view

Anymedi Solution possesses a differentiated foundation: a pedigreed Asan Medical Center spinoff origin, over 3,000 clinical study records, and the most extensive new medical technology certifications and insurance listings among domestic digital health peers.

Fiscal 2024's 21% revenue growth and 42% operating loss reduction partially validate the business model, and the AI surgical robotics push alongside Innofit's global expansion reinforce a credible medium-to-long-term growth narrative.

However, unbroken operating losses since founding, a greater-than-80% stock decline from mid-2025 levels, and daily turnover of barely KRW 111,570 collectively indicate a severe erosion of market participant confidence.

Structural barriers—multi-year regulatory and adoption timelines for the AI surgical robot—stand between the strategic vision and material earnings impact. A KOSDAQ transfer listing and operational breakeven remain necessary preconditions for any meaningful re-rating.

At this juncture, while the underlying technology and strategic direction merit acknowledgment, a cautious posture is warranted until financial sustainability, liquidity structure, and a concrete breakeven roadmap are clearly established.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 10 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.